142 related articles for article (PubMed ID: 7805179)
1. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
Cusack BJ; Young SP; Olson RD
Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
[TBL] [Abstract][Full Text] [Related]
2. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
Cusack BJ; Young SP; Vestal RE; Olson RD
Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
4. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol?
Cusack BJ; Mushlin PS; Voulelis LD; Li X; Boucek RJ; Olson RD
Toxicol Appl Pharmacol; 1993 Feb; 118(2):177-85. PubMed ID: 8441996
[TBL] [Abstract][Full Text] [Related]
5. Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart.
Platel D; Bonoron-Adèle S; Robert J
Pharmacol Toxicol; 2001 May; 88(5):250-4. PubMed ID: 11393585
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
[TBL] [Abstract][Full Text] [Related]
7. Aging increases the cardiotoxicity of daunorubicin and daunorubicinol in the rat.
Cusack BJ; Mushlin PS; Johnson CJ; Vestal RE; Olson RD
J Gerontol A Biol Sci Med Sci; 1996 Sep; 51(5):B376-84. PubMed ID: 8808986
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
Maniez-Devos DM; Baurain R; Lesne M; Trouet A
J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
Robert J; Rigal-Huguet F; Hurteloup P
Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and deoxydaunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit.
Gewirtz DA; Yanovich S
Biochem Pharmacol; 1986 Nov; 35(22):4059-64. PubMed ID: 3778526
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of daunorubicinol in the rabbit: comparison with daunorubicin.
Maniez-Devos DM; Baurain R; Trouet A; Lesne M
J Pharmacol; 1986; 17(1):14-20. PubMed ID: 3713197
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L
Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528
[TBL] [Abstract][Full Text] [Related]
13. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.
Eksborg S; Ehrsson H; Andersson B; Beran M
J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557
[TBL] [Abstract][Full Text] [Related]
14. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit.
Hulhoven R
Biomedicine; 1978 Jul; 29(5):164-7. PubMed ID: 719130
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.
Hempel G; Relling MV; de Rossi G; Stary J; De Lorenzo P; Valsecchi MG; Barisone E; Boos J; Pieters R
Pediatr Blood Cancer; 2010 Mar; 54(3):355-60. PubMed ID: 19731319
[TBL] [Abstract][Full Text] [Related]
16. HPLC determination of daunorubicin and daunorubicinol in human plasma.
Hulhoven R; Desager JP
Biomedicine; 1977 Apr; 27(3):102-4. PubMed ID: 890014
[TBL] [Abstract][Full Text] [Related]
17. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
[TBL] [Abstract][Full Text] [Related]
18. Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.
Paul C; Baurain R; Gahrton G; Peterson C
Cancer Lett; 1980 Jun; 9(4):263-9. PubMed ID: 6930988
[TBL] [Abstract][Full Text] [Related]
19. Distribution and metabolism of rubidazone and daunorubicin in mice.
Baurain R; Deprez-De Campeneere D; Trouet A
Cancer Chemother Pharmacol; 1979; 2(1):37-41. PubMed ID: 498418
[TBL] [Abstract][Full Text] [Related]
20. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine.
Charlier HA; Olson RD; Thornock CM; Mercer WK; Olson DR; Broyles TS; Muhlestein DJ; Larson CL; Cusack BJ; Shadle SE
Mol Pharmacol; 2005 May; 67(5):1505-12. PubMed ID: 15705743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
